Bear Market No Barrier: Eli Lilly to Invest $2.1 Billion in New Indiana Facilities to Support Approved Drug Production

Unlike the trend of pharmaceutical companies clustering together, Eli Lilly, headquartered in a small city in the American Midwest, has always maintained its distance from mainstream pharmaceutical hubs. Recently, as the biotech industry continues to bear the brunt of a prolonged bear market, an increasing number of companies are undergoing restructuring and layoffs. However, Eli Lilly is "swimming against the tide," investing billions to expand its facilities and hire new staff.

In January this year, Eli Lilly invested $1 billion to build a new factory in North Carolina for the production of injectable products and devices. As Eli Lilly begins large-scale production expansion in the United States, a recent investment has drawn industry attention.

On Wednesday, Eli Lilly and Company announced that it would invest $2.1 billion to build two new production facilities in the LEAP Lebanon Innovation Research Zone in Boone County, Indiana.

Eli Lilly said in a press release that it expects these facilities to expand its production network for new models such as active ingredients and gene therapies. These manufacturing bases will help Eli Lilly meet the growing demand for current and future medicines.

When discussing the upcoming establishment of facilities, Eli Lilly and Company boasted about the 17 new drugs approved in the past eight years, including tirzepatide (now renamed Mounjaro), which was approved this month for the treatment of type 2 diabetes.

In addition, Eli Lilly and Company is expected to staff the facility with 500 new employees. The company currently employs more than 3,700 manufacturing workers in Indiana.

Eli Lilly and Company CEO David Ricks stated, "With over 146 years of history since its founding, Eli Lilly remains committed to investing and innovating in Indiana. These new facilities will enhance our capacity for an expanding pipeline of innovative medicines while creating more high-tech job opportunities for the local community."

As early as 2019, Eli Lilly disclosed plans to expand production in Indiana. Since then, Eli Lilly has invested heavily in research and manufacturing around Indianapolis. The total investment exceeded $2.5 billion over five years, creating additional manufacturing jobs.

Eli Lilly Plans to Collaborate with Several Institutions, Including the Indiana Economic Development Corporation, on Its Latest Project in Boone County. Eli Lilly Stated That Every New Position Within the Company Would Generate "Four Additional Indirect Jobs." According to Eli Lilly's Estimates, the Project Will Require Approximately 1,500 Construction Jobs During the Factory's Construction Period.

Besides the United States, Eli Lilly and Company has also been making substantial investments in its production network. At the end of January, the company announced that it would invest approximately 400 million euros (445.3 million US dollars) in a new biological raw materials plant in Limerick, Ireland.

Shortly thereafter, Eli Lilly sent a telegram stating that it would invest $1 billion to build a new facility in Concord, North Carolina, with plans to hire approximately 600 new employees there. The entire project will encompass over 800,000 square feet across a five-story building, including manufacturing facilities, logistics and packaging space, a quality control laboratory, and a central utility plant.

The new facility will enable the company to increase the development and production of life-saving drugs, providing full equipment assembly and final packaging for late-stage candidates, manufacturing parenteral (injectable) products and devices, and enhancing the pharmaceutical company’s long-term capacity to meet supply chain diversity needs and its manufacturing capabilities.

The construction plan for this factory began in 2022 and will take several years to complete. Eli Lilly anticipates "increased investment in production in the future to meet the growing demand for drugs treating diabetes, Alzheimer's disease, cancer, and autoimmune diseases."

At the same time, shortly after the CEO of Eli Lilly made comments about Indiana, the company invested domestically in the United States.

Over the past five years, Eli Lilly and Company has invested $4 billion in global manufacturing, including more than $2 billion in the United States. The company currently has seven manufacturing sites in the U.S. and eight international manufacturing sites worldwide. In 2020, Eli Lilly invested $470 million in Research Triangle Park, North Carolina.

In April, Ricks said in a speech at The Economic Club of Indiana: "Our state’s education system is not strong, and I believe we can enhance the ability to retrain the workforce. Overall, in terms of health, life, and inclusiveness, our state ranks low nationwide. Moreover, workforce readiness related to retraining is also a burden for us." This statement was also quoted by Wish-TV, an Indianapolis news outlet.

He pointed out that the medical costs in Indiana also exceed those of neighboring states, making it difficult for Indiana to attract potential employers.

Source of the article: Tongxieyi

Author: WriteEase Jun Translation

Editor: Qijin

This article is a reprint from PharmaKoo. The images and text are owned by the original author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding content, copyright, or other problems, please contact us via the message board on our website, and we will delete the content as soon as possible.